Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature

We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, regorafenib was given in the third line setting. Surprisingly, the patient had a prolonged partial respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Korphaisarn, Krittiya, Loree, Jonathan M., Nguyen, Van, Coulson, Ryanne, Holla, Vijaykumar, Litzenburger, Beate C., Chen, Ken, Mills, Gordon B., Maru, Dipen M., Meric-Bernstan, Funda, Shaw, Kenna R. Mills, Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593691/
https://www.ncbi.nlm.nih.gov/pubmed/28915719
http://dx.doi.org/10.18632/oncotarget.18357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593691/
https://www.ncbi.nlm.nih.gov/pubmed/28915719
http://dx.doi.org/10.18632/oncotarget.18357

Ejemplares similares